OnCo
ideasIdea

A translation fund for academic surgical devices and radiotherapy technology

New surgical tools, imaging probes and radiotherapy hardware invented in universities rarely attract investors. A dedicated fund would pay for prototyping, safety testing and first-in-human studies.

A fund for academic devices and techniques in cancer surgery and radiotherapy: intraoperative imaging probes, margin-assessment tools, low-cost brachytherapy applicators, FLASH-capable beam systems, adaptive planning software, robotic instruments. It pays for design-for-manufacture, ISO 13485 quality systems, biocompatibility and safety testing and IDEAL-framework early studies. Device venture capital is thin outside cardiology and orthopaedics, and academic engineering groups have no path to first-in-human without it. The fund would work with translational institutes and the surgical and radiotherapy trials networks proposed elsewhere in this wave.

Hypothesis
A device translation fund of $50 million over five years brings at least fifteen academic cancer surgery or radiotherapy technologies to first-in-human evaluation and at least five to a randomised or IDEAL stage 3 study, compared with a handful in the preceding five years.
Rationale
Fluorescence-guided surgery agents and intraoperative margin tools have taken well over a decade to reach approval largely for lack of translational funding; where public funding existed (for example the UK's NIHR i4i programme) academic devices reached patients. Oncology devices are a market failure because they are hard to patent broadly and slow to reimburse.
What would test it
Fund a first cohort of ten technologies and track time to first-in-human, regulatory milestones and subsequent trials against a matched set of unfunded academic devices.
Maturity
speculative
Who has to act
philanthropy
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

10top